|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 122.42 CHF | -1.73% |
|
-3.45% | +11.70% |
| 07-14 | US FDA approves Celcuity's breast cancer drug | RE |
| 07-14 | Where would AI lead Pharma in the long run? |  |
| Market Cap | 277B 242B 224B 207B 390B 26,645B 397B 2,672B 1,049B 13,047B 1,042B 1,019B 44,924B | P/E 2026 * |
21.2x | P/E 2027 * | 17.9x |
|---|---|---|---|---|---|
| Enterprise Value | 309B 270B 250B 231B 435B 29,719B 443B 2,981B 1,169B 14,552B 1,162B 1,136B 50,107B | EV / Sales 2026 * |
5.44x | EV / Sales 2027 * | 5.08x |
| Free-Float |
91.66% | Yield 2026 * |
2.9% | Yield 2027 * | 3% |
Last Transcript: Novartis AG
| 1 day | -1.73% | ||
| 1 week | -3.45% | ||
| Current month | -3.29% | ||
| 1 month | +0.28% | ||
| 3 months | +1.78% | ||
| 6 months | +5.48% | ||
| Current year | +11.70% |
| 1 week | 122.02 |  | 125.8 |
| 1 month | 117.96 | | 128.92 |
| Current year | 107.68 | | 131 |
| 1 year | 91.2 | | 131 |
| 3 years | 81.1 | | 131 |
| 5 years | 72.84 | | 131 |
| 10 years | 65.09 | | 131 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/02/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 16/03/2026 |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 16/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 01/01/2015 |
| Director/Board Member | 69 | 01/01/2016 | |
Ton Büchner
BRD | Director/Board Member | 61 | 01/01/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-18 | Sell | -5,200 | 0.0003% | |||
| 05-04 | Sell | 6,800 | 0.0003% | |||
| 02-17 | Sell | 30,743 | 0.0015% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.73% | -3.45% | +26.95% | +44.09% | 281B | |
| -2.48% | -6.72% | +44.19% | +156.43% | 1,054B | |
| -1.52% | -5.01% | +61.87% | +58.79% | 621B | |
| -1.30% | -3.88% | +27.81% | +79.97% | 438B | |
| -1.12% | -3.68% | +26.89% | +20.58% | 325B | |
| -1.95% | -13.92% | +15.96% | +19.76% | 262B | |
| -1.45% | -2.37% | -27.87% | -39.87% | 219B | |
| -1.44% | -3.49% | +19.60% | +56.20% | 195B | |
| -1.04% | -4.63% | +16.01% | +68.47% | 163B | |
| -0.94% | +0.75% | -4.34% | -33.23% | 140B | |
| Average | -1.08% | -3.66% | +20.71% | +43.12% | 369.57B | |
| Weighted average by Cap. | -0.85% | -4.56% | +31.75% | +72.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 56.83B 49.66B 45.91B 42.41B 79.87B 5,458B 81.32B 547B 215B 2,673B 213B 209B 9,203B | 60.24B 52.64B 48.67B 44.96B 84.67B 5,786B 86.21B 580B 228B 2,833B 226B 221B 9,756B |
| Net income | 14.08B 12.3B 11.37B 10.51B 19.79B 1,352B 20.15B 136B 53.22B 662B 52.88B 51.71B 2,280B | 15.64B 13.67B 12.64B 11.68B 21.99B 1,503B 22.39B 151B 59.13B 736B 58.76B 57.46B 2,533B |
| Net Debt | 32B 27.97B 25.85B 23.89B 44.98B 3,074B 45.8B 308B 121B 1,505B 120B 118B 5,183B | 28.5B 24.91B 23.03B 21.27B 40.06B 2,738B 40.79B 275B 108B 1,341B 107B 105B 4,616B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/07/26 | CHF 122.42 | -1.73% | 2,431,098 |
| 13/07/26 | CHF 124.58 | +0.24% | 2,143,959 |
| 10/07/26 | CHF 124.28 | -0.02% | 2,334,841 |
| 09/07/26 | CHF 124.30 | -1.27% | 2,233,204 |
| 08/07/26 | CHF 125.90 | -0.71% | 2,243,169 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
